An Open Label, Randomized Phase I/IIa Trial Evaluating MK-0646 in Combination With Erlotinib (TARCEVA) for Patients With Recurrent Non-Small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Dalotuzumab (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck & Co
- 31 Mar 2012 Additional trial location added as reported by European Clinical Trials Database.
- 31 Mar 2012 Planned number of patients changed from 68 to 211 as reported by European Clinical Trials Database.
- 21 Feb 2012 Actual end date changed from 1 Mar 2011 to 1 Feb 2012 as reported by ClinicalTrials.gov.